BACKGROUND: @entity172 administration is known to increase serum @entity412 concentrations. This study measured changes in lipoproteins of @entity1 with @entity263 treated with @entity172 to determine whether the increased @entity412 concentrations are associated with atherogenic lipoprotein patterns. METHODS: Fifteen @entity1 (52-87 years) with histologically diagnosed @entity263 received @entity18830 (250 mg/day). Serum samples were collected before and after 1 and 2 weeks of treatment. @entity165 and @entity412 profiles of major lipoproteins were determined by HPLC, remnant-like particle @entity165 and @entity412 concentrations by an immunoseparation technique, and apolipoproteins by immunologic methods. RESULTS: @entity172 treatment induced a 63.3% increase in total @entity412 concentrations, which occurred in all major lipoprotein classes with significant increases in HDL- @entity1674 (130.4%), LDL- @entity1674 (60.7%) and VLDL- @entity1674 (56.2%). HDL- @entity165 increased significantly by 26.8%, while LDL- @entity165 decreased (15.6%). Remnant-like particle @entity412 concentrations also increased significantly by 77%, whereas remnant-like particle @entity165 concentrations remained unchanged. Apolipoproteins A-I and A-II increased; apolipoprotein E and Lp(a) decreased. CONCLUSIONS: The techniques used here conveniently demonstrated that short-term @entity172 treatment in @entity263 @entity1 resulted in @entity412 enrichment of all major lipoprotein classes but did not induce changes in the lipoprotein profiles generally recognized as increasing risk for @entity65 , except for the elevation of plasma @entity412 and remnant-like particle @entity412 .

XXXX treatment of @entity263 increases @entity1674 in lipoproteins as demonstrated by HPLC and immunoseparation techniques.

@entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen', 'Estrogen'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides'] @entity18830 :: ('MESH:C004955', 'Chemical') :: ['diethylstilbestrol diphosphate'] @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['Cholesterol', 'cholesterol']
@entity172 :: (MESH:D004967,Chemical) :: ['Estrogen']
